Compare Transocean Ltd (RIG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Transocean Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Transocean Ltd trades at $5.55 (market cap $6.19B), while State Street SPDR S&P Biotech ETF trades at $154 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Transocean Ltd for 18 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| RIG | XBI | |
|---|---|---|
Market Cap | $6.19B | $10.11B |
Volume | 30,564,415 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $7.58 | $169.55 |
52-Week Low | $3.08 | $104.99 |
Typical Hold Time | 18 Days | 38 Days |
Enterprise Value | $10.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Transocean (RIG) trades at $5.55, up 2.97% on the day, with a bullish technical signal driven by oscillators. The company reported a Q2 2026 EPS beat but remains unprofitable with a net income margin of -40.24%. Recent news highlights progress on the $5.8 billion Valaris acquisition and new contract awards, supporting cash flow growth. The stock shows mixed analyst sentiment with a 39.06% buy rating.
The outlook is speculative, hinging on successful deleveraging and offshore cycle strength. Investment opportunity lies in cash flow improvement and backlog execution, but risks include high debt, execution challenges from the Valaris deal, and persistent negative profitability. The stock presents a high-risk, event-driven play for investors betting on an offshore drilling recovery.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
